Abstract
This investigation compares how effectively ⁶⁸Ga-PSMA and ⁶⁸Ga-DOTA-RM2 PET/MRI identify prostate cancer (PCa) recurrence following initial therapy and examines how the results of these two tracers relate to clinical and pathological variables. Thirty-five men experiencing biochemical relapse (BCR) underwent restaging with ⁶⁸Ga-PSMA PET/MRI, and 31 of them also completed a ⁶⁸Ga-DOTA-RM2 PET/MRI examination within a period of up to 16 days (mean interval: 3 days; range: 2–16 days).
Introduction: The Challenge of Biochemical Recurrence
When prostate cancer returns after initial treatment—a state known as biochemical recurrence (BCR)—clinicians face a significant diagnostic hurdle. While rising Prostate-Specific Antigen (PSA) levels signal the cancer's return, conventional imaging often fails to pinpoint the exact location of small tumors, especially when PSA levels remain low. This "needle in a haystack" problem necessitates more sensitive molecular imaging techniques.
Two primary molecular targets have emerged: the Prostate-Specific Membrane Antigen (PSMA) and the Gastrin-Releasing Peptide Receptor (GRPR), the latter targeted by the ⁶⁸Ga-DOTA-RM2 tracer. While PSMA is the current gold standard, some cancers exhibit low PSMA expression. This study provides a head-to-head comparison of these two tracers using state-of-the-art integrated PET/MRI technology to determine their relative efficacy in locating recurrent disease.
Methods: A Dual-Tracer PET/MRI Approach
The researchers conducted a prospective study involving 35 men (average age 70) with BCR. A dual-tracer protocol was employed, where 31 participants underwent two separate PET/MRI scans—one with ⁶⁸Ga-PSMA and one with ⁶⁸Ga-DOTA-RM2—within a mean interval of three days.
All examinations were performed on a fully integrated 3-Tesla PET/MRI system. This hardware allows for the simultaneous acquisition of metabolic data (PET) and high-resolution anatomical and functional data (MRI), providing a comprehensive view of potential recurrence sites. Findings were validated against a "truth" standard comprising clinical follow-up, subsequent imaging, and PSA response to targeted therapies.
Results: PSMA vs. RM2 Performance
The study revealed a clear dominance of the PSMA tracer in detecting recurrent lesions. PSMA PET/MRI identified recurrence in 74% of the cohort, compared to 48% for the RM2 tracer. At the lesion level, the difference was even more pronounced: PSMA identified 95 lesions, while RM2 found only 41.
Statistical analysis confirmed these differences were significant for both patient-level (p = 0.016) and lesion-level (p = 0.002) detection. In cases of discordance (where only one scan was positive), PSMA was the sole positive indicator in 10 out of 11 instances, with 9 of those confirmed as genuine cancer during follow-up.
Discussion: Clinical and Pathological Correlations
Interestingly, the aggressiveness of the original cancer (Gleason score) did not predict the success of the scans. Instead, the PSA doubling time (DT)—the rate at which PSA levels rise—was a strong predictor of PSMA positivity (AUC = 0.77). Faster rising PSA levels significantly increased the likelihood of identifying lesions. Furthermore, the total burden of PSMA-positive lesions correlated strongly with PSA metrics, suggesting that PSMA PET/MRI provides valuable prognostic information beyond simple localization.
Conclusion and Future Directions
While ⁶⁸Ga-PSMA remains the superior target for detecting recurrent prostate cancer, this study highlights the potential of integrated PET/MRI in the restaging process. Limitations include the relatively small sample size (n=35) and the lack of histopathological confirmation for all detected lesions.
Future research should explore larger cohorts to identify specific patient subgroups where RM2 might offer complementary value. Additionally, deeper integration of multiparametric MRI data alongside PET tracers could further enhance diagnostic accuracy and personalized treatment planning for men with biochemical recurrence.
Summary updated